Oral Aleniglipron Reduced Weight at 36 Weeks - Takeaways - MDSpire

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

  • By

  • Kathryn Wighton

  • July 16, 2026

  • 6 min

Share

  • 1

    Aleniglipron reduced body weight by 9% to 12% at 36 weeks in adults with obesity or overweight, compared to 1% with placebo.

  • 2

    The ACCESS trial involved 230 patients, aged 18 to 79 years, with a mean BMI of 39.5 kg/m² and a mean weight of 114.8 kg.

  • 3

    Gastrointestinal adverse events were common, occurring in 79% to 89% of aleniglipron-treated patients, with nausea being the most frequent.

  • 4

    At week 56, mean weight loss was 13.3%, 16.2%, and 15.3% for patients initially assigned to 45 mg, 90 mg, and 120 mg, respectively.

  • 5

    The study had limitations, including a predominantly White population and lower female participation compared to other obesity trials.

Original Source(s)

Oral Aleniglipron Reduced Weight at 36 Weeks

  • by Kathryn Wighton

  • July 16, 2026

Related Content

FDA Approves New Treatment for Thyroid Eye Disease

Phase 3 THRIVE and THRIVE-2 trials supported approval following improvements in proptosis and diplopia in active and chronic disease.

GCS May Expand CTRCD Assessment

Award-winning ASE abstract highlights GCS when GLS assessment is limited by suboptimal apical windows.

How Does Social Media Influence Health Decisions?

National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.